A pooled analysis of exenatide use and risk of acute pancreatitis

References

• Bloomgren G, Braun D, Kolterman O. Exenatide BID and rare adverse events. N Eng J Med 2008;358:1971-2
   Web of Science ®Google Scholar
• Cure P, Pileggi A, Alejandro R, et al. Exenatide BID and rare adverse events. N Eng J Med 2008;358:1969-72
   PubMed Web of Science ®Google Scholar
• Denker PS, Dimarco PE. Exenatide BID (Exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006;29:471
   PubMed Web of Science ®Google Scholar
• Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide BID use. Diabetes Obes Metab 2011;13:559-66
   PubMed Web of Science ®Google Scholar
• Dore DD, Seeger JD, Chan KA. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide BID or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
   PubMed Web of Science ®Google Scholar
• Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide BID or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54
   PubMed Web of Science ®Google Scholar
• Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med 2012;29:1412-18
   PubMed Web of Science ®Google Scholar
• Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-9
   PubMed Web of Science ®Google Scholar
• Tatarkiewicz K, Belanger P, Gu G, et al. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks. Diabetes Obes Metab 2013;15:417-26
   PubMed Web of Science ®Google Scholar
• Yu X, Tang H, Huang L, et al. Exenatide-induced chronic damage of pancreatic tissue in rats. Pancreas 2012;41:1235-40
   PubMed Web of Science ®Google Scholar
• Vrang N, Jelsing J, Simonsen L, et al. The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab 2012;303:E253-64
   PubMed Web of Science ®Google Scholar
• Gier B, Matveyenko AV, Kirakossian D, et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 2012;61:1250-62
   PubMed Web of Science ®Google Scholar
• Tatarkiewicz K, Smith PA, Sablan EJ, et al. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2010;299:E1076-86
   PubMed Web of Science ®Google Scholar
• Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010;53:153-9
   PubMed Web of Science ®Google Scholar
• Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-604
   PubMed Web of Science ®Google Scholar
• Byetta prescribing information. Available at: http://www.byettahcp.com/index.jsp [Last accessed 6 October 2008]
   Google Scholar
• Dore DD, Chaudhry S, Hoffman C, Seeger JD. Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus. Pharmacoepidemiol Drug Saf 2011;20:209-13
   PubMed Web of Science ®Google Scholar
• Brenner H, Gefeller O. Use of the positive predictive value to correct for disease misclassification in epidemiologic studies. Am J Epidemiol 1993;138:1007-15
   PubMed Web of Science ®Google Scholar
• Selvin S. Practical biostatistical methods. Belmont CA, USA: Duxbury Press, 1995
   Google Scholar
• Noel RA, Braun DK, Patterson RE, Bloomgren G. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective, cohort study. Diabetes Care 2009;32:834-8
   PubMed Web of Science ®Google Scholar
• Sandzen B, Rosenmuller M, Haapamaki M, et al. First attack of acute pancreatitis in Sweden 1988–2003: incidence, aetiological classification, procedures and mortality – a register study. BMC Gastroenterol 2009;9:18
   PubMed Web of Science ®Google Scholar
• Tenner S, Steinberg W. Drug-induced pancreatitis. In: Beger HG, Warshaw A, Carr-Lock D, et al. (eds). The Pancreas. Vol 2. Oxford, UK; Malden, MA: Blackwell Science, 1998:331-42
   Google Scholar
• Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol 2005;39:709-16
   PubMed Web of Science ®Google Scholar
• Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet 2008;371:143-52
   Google Scholar
• Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
   PubMed Web of Science ®Google Scholar
• Jurek AM, Greenland S, Maldonado G. How far from non-differential does exposure or disease misclassification have to be to bias measures of association away from the null? Int J Epidemiol 2008;37:382-5
   PubMed Web of Science ®Google Scholar
• Hauner H, Köster I, von Ferber L. Frequency of ‘obesity' in medical records and utilization of out-patient health care by ‘obese' subjects in Germany. An analysis of health insurance data. Int J Obes Relat Metab Disord 1996;20:820-4
   PubMed Web of Science ®Google Scholar
• Blomgren KB, Sundstrom A, Steineck G, Wiholm BE. Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care 2002;25:298-302
   PubMed Web of Science ®Google Scholar
• Pelli H, Lappalainen-Lehto R, Piironen A, et al. Risk factors for recurrent acute alcohol-associated pancreatitis: a prospective analysis. Scand J Gastroenterol 2008;43:614-21
   PubMed Web of Science ®Google Scholar
• Walker AM. Observation and Inference. Newton: Epidemiology Resources Inc., 1991:120-4
   Google Scholar
• Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291-303
   PubMed Web of Science ®Google Scholar
• Green MS. Use of predictive value to adjust relative risk estimates biased by misclassification of outcome status. Am J Epidemiol 1983;117:98-105
   PubMed Web of Science ®Google Scholar
• Crystal S, Akincigil A, Bilder S, Walkup JT. Studying prescription drug use and outcomes with Medicaid claims data: strengths, limitations, and strategies. Med Care 2007;45:S58-65
   PubMed Web of Science ®Google Scholar